Adagene Inc.
ADAG- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818838
In the last 90 days, Adagene Inc. insiders filed 4 open-market purchases and 0 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $81.0M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Adagene Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- −1 vs. Q4 2021
- Shares held
- 8.39M
- +17.8K (+0.2%) vs. Q4 2021
- Total value
- $29.7M
- −$37.6M (−55.9%) vs. Q4 2021
- New holders
- 1
- 3 more added
- Sold out
- 2
- 6 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ADAG on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 35 | $81.0M |
| Q1 2026 | 25 | $9.70M |
| Q4 2025 | 17 | $6.03M |
| Q3 2025 | 17 | $11.3M |
| Q2 2025 | 15 | $11.8M |
| Q1 2025 | 14 | $11.6M |
| Q4 2024 | 15 | $20.3M |
| Q3 2024 | 13 | $25.3M |
| Q2 2024 | 14 | $33.7M |
| Q1 2024 | 17 | $34.3M |
| Q4 2023 | 11 | $15.5M |
| Q3 2023 | 10 | $6.16M |
| Q2 2023 | 10 | $6.02M |
| Q1 2023 | 11 | $6.02M |
| Q4 2022 | 9 | $5.58M |
| Q3 2022 | 11 | $7.60M |
| Q2 2022 | 15 | $15.4M |
| Q1 2022 | 15 | $29.7M |
| Q4 2021 | 16 | $67.3M |
| Q3 2021 | 19 | $126.6M |
| Q2 2021 | 16 | $80.5M |
| Q1 2021 | 27 | $115.5M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Adagene Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 4,992 | $17.0K | 0.00% | +3,714+290.6% | Added |
| Geode Capital Management, LLC | 10,309 | $36.0K | 0.00% | +10,309 | New |
| E Fund Management Co., Ltd. | 19,310 | $69.0K | 0.00% | −34,775−64.3% | Reduced |
| Tudor Investment Corp Et Al | 25,976 | $91.0K | 0.00% | 00.0% | Unchanged |
| Capital International Sarl | 28,392 | $101.0K | 0.01% | 00.0% | Unchanged |
| Hudson Bay Capital Management LP | 228,470 | $816.0K | 0.01% | −103,073−31.1% | Reduced |
| General Atlantic LLC | 264,000 | $924.0K | 0.01% | 00.0% | Unchanged |
| Capital International Inc | 302,808 | $1.08M | 0.01% | −2,068−0.7% | Reduced |
| Matthews International Capital Management LLC | 648,000 | $2.31M | 0.32% | −159,600−19.8% | Reduced |
| Strategic Vision Investment Ltd | 779,133 | $2.78M | 10.15% | +622,633+397.8% | Added |
| Artal Group S.A. | 1,000,000 | $3.50M | 0.15% | 00.0% | Unchanged |
| Capital International Investors | 1,112,200 | $3.97M | 0.00% | −25,332−2.2% | Reduced |
| FMR LLC | 1,238,173 | $4.42M | 0.00% | −14,892−1.2% | Reduced |
| SC China Holding Ltd | 1,343,364 | $4.70M | 0.59% | 00.0% | Unchanged |
| Morgan Stanley | 1,386,473 | $4.85M | 0.00% | +794+0.1% | Added |
| OrbiMed Advisors LLC | 0 | $0 | 0.00% | −263,176−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −16,753−100.0% | Sold out |